*CURRICULUM VITAE*

NAME: Richard L. Edelson, M.D.

BORN: December 19, 1944

EDUCATION: 1962-1966 B.A. Hamilton College

Major: Chemistry

Minor: British and American Public Address

1966-1970 M.D. Yale University School of Medicine

CAREER: 1970-1971 Intern (Internal Medicine)

University of Chicago

1971-1972 Resident (Dermatology)

Harvard University Hospitals

1972-1975 Research Associate, Laboratory of Immunology,

National Institute of Allergy & Infectious Diseases

National Institutes of Health

1975-1976 Senior Resident in Dermatology

Columbia-Presbyterian Hospital

1976-1978 Assistant Professor of Dermatology

Columbia College of Physicians and Surgeons

1978-1980 Associate (Tenured) Professor of Dermatology

Columbia College of Physicians and Surgeons

1980-1985 Deputy Director

General Clinical Research Center

Columbia College of Physicians and Surgeons

1980-1985 Professor (Tenured) and Director of Research

Department of Dermatology

Columbia College of Physicians and Surgeons

November 2000 - 2003 Deputy Dean for Clinical Affairs

Yale School of Medicine

July 2003 - March 2009 Director, Yale Comprehensive Cancer Center

Yale School of Medicine

January 1986 - Present Aaron Lerner Professor (Tenured) and Chair

Department of Dermatology

Yale School of Medicine

BOARD CERTIFICATION:

American Board of Dermatology

MAJOR RESEARCH INTERESTS:

Immunology of Cutaneous T-Cell Lymphoma

Clinical Investigation of Autoimmune Disorders

Epidermal T-Cell Interactions

Cancer Immunotherapy

Extracorporeal Photochemotherapy

LEADERSHIP: YALE MEDICAL CENTER COMMITTEES:

Chair, Search Committee for Chief of Medical Oncology

Chair, Search Committee for Chairman of Internal Medicine

Chair, Search Committee for Yale-New Haven Hospital Chief of Staff

Chair, Search Committee for Faculty Practice COO

Chair, Search Committee for Yale Cancer Center Director

Member, Ovarian Cancer SPORE, Internal Advisory Committee

Member, Board of Trustees, Yale-New Haven Hospital

President’s Council, Yale-New Haven Hospital

Steering Committee, Faculty Practice Plan

Faculty Representative, Yale-New Haven Hospital Budget & Finance Committee

Steering Committee - Graduate Program in Investigative Medicine 1999 -

Committee on Emergency Medicine Proposal - 1999

Director, Yale Comprehensive Cancer Center Lymphoma Research Program

Yale Medical Group Board of Governors

Member of the New Clinical Program Development Fund - YNHH and Yale Medical School

Steering Committee for Amistad Clinical Program Model Committee

Practice Standards Work Group, 2012-present

Senior Clinical and YNHH Leadership Group, 2012-present

PROFESSIONAL HONORS:

Elected Member of the American Society for Clinical Investigation

Elected Member of the Association of American Physicians

Elected Member of the Interurban Club

Irma T. Hirschl Career Investigator

McKee Research Prize

Citation Classic

Dohi Award (Japanese Dermatologic Society)

British Association of Dermatologists Annual Lecturer

National Cancer Society Merit Award

British Association of Dermatologists (Honorary Foreign Member)

Dozor Visiting Scholar, Ben-Gurion University (Israel)

Elected American Association for the Advancement of Science Fellow 1998

M.H. Samitz Lecturer 2001, University of Pennsylvania

Consult Professor of Shanghai Second Medical University 2002

Annual Oration of the St. John’s Hospital Dermatological Society, London, December 2003

Aaron B. and Marguerite Lerner Professor of Dermatology, May 2008

Faculty of 1000 Original Publications of Special Importance, 2010, 2015

Yale University Leadership in Biomedicine Distinguished Lecturer, February 2012

Castle Connolly National Physician of the Year Award for Clinical Excellence, 2012

American Skin Association, Skin Cancer and Melanoma Research Achievement Award, 2014

Dermatology Foundation 2015 Discovery Award

Lifetime Honoree, Society for Investigative Dermatology

David Martin Carter Mentor Award, 2016

American Skin Foundation National Mentor-of-the-Year Award 2017

SID (National) Rothman Memorial Award for Career Accomplishments, 2019

EXTERNAL INSTITUTIONAL ADVISORY BOARDS

Harvard Medical School, Massachusetts

Mt. Sinai School of Medicine, New York

Perelman School of Medicine, University of Pennsylvania

Oregon Health & Science University

Massachusetts General Hospital

University of Colorado

Castle Connolly Top Doctors

EDITORIAL BOARDS:

Journal of Investigative Dermatology

Journal of Cutaneous Pathology

Journal of Dermatologic Surgery and Oncology

Journal of The American Academy of Dermatology

British Journal of Dermatology

REVIEWER FOR NIH STUDY SECTION:

General Medicine A (1986-90)

Multiple Ad Hoc Site Visits and Grants

NATIONAL EXECUTIVE COMMITTEES:

National Cancer Institute Liaison for AAD

Association of Professors of Dermatology

Dermatology Foundation Leaders Society

Nominating Committee of the Association of Professors of Dermatology

Dermatology Foundation Past President

Dermatology Foundation Past Vice President

Dermatology Foundation Past Secretary-Treasurer

MEDICAL SOCIETIES:

American Academy of Dermatology

American Federation of Clinical Research

Dermatology Foundation Leader's Society

Society for Investigative Dermatology

American Dermatology Association

American Society for the Advancement of Science

Harvey Society

National Institute of Health - FAES

New York Academy of Sciences

New England Dermatological Society

New Haven Medical Association

Interurban Clinical Club

YALE UNIVERSITY POSITIONS

Faculty Fellow Timothy Dwight College 1987 - 2018

Faculty Fellow Branford College, Yale College 2018 – present

VISITING PROFESSORSHIPS/Named LECTURESHIPS:

Dohi Lecturer (Japanese Dermatologic Society); Hammamatsu University (Japan); Keio University (Japan), British Association of Dermatologists, St. John's University (England), Japanese Dermatological Society, Kitasato Univ. (Japan), Univ. of Seoul (South Korea), Harvard (2), London Univ., Univ. of Kiel (W. Germany), Hosp. St. Louis (Paris), NYU (5), Cornell (2), Downstate, Einstein (5), Western Reserve, UCLA, Univ. of Calif (San Diego), Univ. of Michigan (2), Dartmouth (New Hampshire), Univ. of Pa (2), Emory (2), Univ. of Texas (Dallas), Univ. of Cincinnati, Brown, Tufts, Mt. Sinai, Cleveland Clinic, Mayo Clinic, Univ. of Bogota (Colombia), Univ. of Minnesota, Medical College S. Carolina, NIH (4), Univ. of Puerto Rico (2), Brooke Army Hospital, University of Vancouver, Medical College of Wisconsin, Karolinska Institute, Stockholm; University Dell Aquila (Rome); University of Miami; Northwestern; Dozor Visiting Scientist Ben Gurion University (Israel); University of Padua (Italy); University of Trujillo (Peru); Vanderbilt, Columbia, Boston University, Henry Ford Hospital, National Institutes of Health (4); IV Prague Dermatological Meeting (Prague); Fifth Asian Dermatologic Congress (Beijing, China); Annual Eastern Regional Meeting of the Japanese Dermatological Association (Hammamatsu, Japan); Wally Lobitz Lecturer, *Immunotherapeutic Jiu Jitsu: Using the Strength of the Immunologic System to Control Its Own Aberrations 2) Methods for Deciphering the Immuno-Enhancing Effects of Psoralens 3) The Cutaneous T Cell Lymphoma Algorithm: Decoding Inflammatory Diseases of the Skin,* Oregon Dermatology Society (Portland, Oregon); I International Dermatological Meeting Cuenca, Ecuador, February 1999; University of Puerto Rico, *1) The Clinically Relevant Immunobiology of Cutaneous T Cell Lymphoma 2) Vaccination against Tumor Antigens of Cutaneous T Cell Lymphoma,* San Juan, Puerto Rico February 2000; Henry Ford Hospital, Detroit, *1) The Clinically Relevant Immunobiology of Cutaneous T Cell Lymphoma 2) Vaccination against Tumor Antigens of Cutaneous T-cell Lymphoma,* April 2000; Mt. Sinai School of Medicine, New York, *Vaccination Therapy for Cutaneous T-Cell Lymphoma and Autoreactive Skin Disease,* December 2000; Congress of the European Society for Haemapheresis (Malmo, Sweden); State University of New York, Brooklyn, *Immunologic Jiu-Jitsu: Using the Strength of the Immune System to Correct Its Own Aberrations,*  May 2001; State of the Art on Cutaneous Lymphoma, Cambridge, MA September 28, 2001 *Use of Apoptotic Malignant T-cells as Immunogens;* Invited H.M. Samitz Lecturer in Cutaneous Medicine, *Immunologic Jiu-Jitsu, Using the Strength of the Immune System to Correct Its Own Aberrations,* Philadelphia, October, 2001; Annual Meeting of the Chilean Society of Dermatology, *Dermatology Practice in the USA-non-university private practice vs. university private practice,* Clinica Alemena, Pucon, Chile, November 2001; British Photodermatology Group/ United Kingdom Skin Lymphoma Group Workshop on Photopheresis, 1) *Mechanism of Action of Photopheresis 2) Future Directions for Photopheresis,* Belfast, Ireland December, 2001; International Symposium Biology & Immunology of Cutaneous Lymphoma, *1) Tumor associated Antigenes in Cutaneous Lymphoma 2) Vaccination therapies,* Berlin January, 2002; Protein Transduction Strategies: Current Principles and Application to Cutaneous T Cell Lymphoma, National Cancer Institute, *Overview of Cutaneous T Cell Lymphoma,* Bethesda, Maryland, February, 2002; Valley of the Sun Conference on Clinical Dermatology, Scottsdale, Arizona, April 2002; Invited Speaker - Dr. Lloyd King Symposium, *The Evolution of CTCL and Extracorporeal Photochemotherapy,* Vanderbilt University, Nashville, Tennessee June 2002; Invited speaker SID, *Deciphering the Mechanism by which Ultraviolet Therapy Increases Malignant Cell Immunogenicity,* Los Angeles, California May 2002; 20th World Congress, Paris, France, July 2002 *Future Directons for Photopheresis*; State of the Art on Cutaneous Lymphomas, Boston, Massachusetts September 2002; Invited Lecturer H&H Dermatology Seminar, Miami, Florida October 2002; Young Leaders in Dermatology *Cutaneous T Cell Lymphoma improved evaluation and treatment: Learning to speak the language of the malignant cells,* Tucson, Arizona, October 2002; Invited Lecturer Shanghai Second Medical University, *The Clinically Relevant Immunobiology of Cutaneous T Cell Lymphoma 2) Vaccination against Pathogenic T Cells, both Malignant and Autoimmune, with Transimmunization/ Photopheresis,* Shanghai, China January 2003; NCI Protein Workshop, International Symposium of Cutaneous Biology and Selective Immunotherapy against CTCL, Washington DC, February, 2003; Invited Lecturer Cell Therapy: the State of Art and New Perspectives Workshop *1) Modulation of Immune System by Extracorporeal Photochemotherapy 2) Transimmunization: Correcting the Flaws of ECP,* Pavia, Italy, May 2003; Invited lecturer Annual Meeting of the YNHH Auxiliary, *Outsmarting Cancer Cells by Learning the Language They Speak,* October, 2003; Invited Lecturer Lymphoma Research Foundation *Cutaneous T Cell Lymphoma and Mycosis Fungoides:* 2003 Educational Forum on Lymphoma, Washington DC, October 25, 2003; Invited Lecturer *International Society for Apheresis*, Nashville, Tennessee, October 30, 2003: 1) *Learning to Outmaneuver Cutaneous T Cell Lymphoma by Deciphering the Language that the Malignant Cells Speak, 2) Transimmunization: patient specific anti-tumor immunotherapy, October 2003;* Invited Hermann Pinkus Lecturer to Michigan State Dermatology Society, Wayne State University, November 12, 2003, 1) *Learning to Outsmart Cutaneous T Cell Lymphoma by understanding the language that the malignant cells speak; 2) Patient Specific Vaccination Against Malignant Cells* ; St. John’s Hospital Dermatological Society, London, December 4, 2003 *Langerhans Cells Appearu to Stimulate CTCL Cell Growth;* Invited Jack & Marjorie Gunn Lectureship, University of Columbia, Missouri, May 2004. *Learning to Outsmart the Malignant Cells of Cutaneous T Cell Lymphoma;* 5th European Congress of Oto-Rhino-Laryngology Head & Neck Surgery, Rhodes, Greece *1) Keynote lecture: Learning to Vaccinate Patients against their own solid tumors 2) Keynote lecture: New Methods of Immunotherapy for Solid Tumors, September 11-17, 2004;* International Symposium on Biology & Immunology of Cutaneous Lymphoma, Berlin, Germany February 3, 2005, *Cutaneous T Cell Lymphoma: proliferation of T-regulatory Cells;* Grand Rounds Norris Cotton Cancer Center, Dartmouth Hitchcock, September 15, 2005; AABB Annual Meeting, Seattle, WA *“Immunotherapy through Extracorporeal Photochemotherapy”* October 15, 2005; Valley of the Sun, Phoenix, Arizona *“Cutaneous T Cell Lymphoma*”, April 4, 2006; 21st World Congress, Buenos Aires, Argentina, “*Vaccination for Cutaneous T Cell Lymphoma,*” October 2, 2007; Arthur C. Curtis Visiting Professor, University of Michigan “Immunoloic Jiu Jitsu – Strides Towards Using Malignant Cells to Immunize Against Themselves,” “Outmaneuvering CTCL Cells by Intercepting and Decoding Their Own Cellular Conversations,” March 12-13, 2008; Grand Rounds Montefiore Hospital “*Striving to Immunize against Cancer,*” April 10, 2008; Medical Grand Rounds, Waterbury Hospital*, “T Cell Lymphoma as a Model for Development of Dendritic Cell-Based Tumor-Specific Immunotherapy,”* September 5, 2008; Grand Rounds, John F. Strahan Lectureship, Johns Hopkins School of Medicine, Dept. of Dermatology, *“Outsmarting Malignant T Cells by Cracking the Code that makes Them Tick,”* October 8, 2008; 12th Congress of the French Society of Hemaphaeresis associated to the 2nd European ECP Meeting, *“ECP – A Physiologic Method for Large Scale Production and Loading of Functional Dendritic Antigen Presenting Cells,”* November 20, 2008; Clinical Immunology Seminar Series, Yale University School of Medicine*, “A Fortuitous Yale Story: Shortcut to Effective Dendritic Cell-Based Immunotherapy Tailored to both Lymphoma and Transplantation,”* March 20, 2009; Dermatology Grand Rounds, Michigan State University, *“T Cell Lymphoma as a Model for Development of Dendritic Cell-Based Tumor-specific Immunotherapy,”* April 15, 2009; Thomas B. Fitzpatrick Memorial Lecture, Department of Dermatology, Harvard Medical School, *“Scientific Clue to the Basis of the Immuno-Modulatory Efficacy of Extracorporeal Photochemotherapy: Efficient large Scale Conversation of Monocytes to Dendritic Antigen Pressing Cells,”* Sept. 17, 2009; Cutaneous Lymphoma Summit, Keynote Address,*“Learning to Outsmart CTCL Cells by Decoding the Language They Speak,”* October 9, 2009; Zackheim Memorial Lecture, Dermatology Grand Rounds, University of California, San Francisco*, “Striving to Outflank CTCL Cells by Learning the Language They Speak,”* October 14, 2009; Yale Cancer Center Grand Rounds, Yale School of Medicine, *“Personalized Dendritic Cell Immunotherapy: Deciphering the Scientific Mechanism of Extracorporeal Photochemotherapy,”* Feb. 2, 2010; Israel Cancer Research Fund (ICRF), New York, NY, *“Scientific Review Panel Meeting,”* March 21-22, 2010; First World Congress of Cutaneous Lymphoma presented by Northwestern University and the International Society of Cutaneous Lymphomas, Chicago, IL, *“Immunology: T-Cell Signaling Dysregulation,”* Sept. 23, 2010; Dowling Club Lecture, Dermatology Grand Rounds, University of CA, Irvine, *“Learning to Outsmart Lymphoma Cells,”* Sept. 29, 2010; Medical Grand Rounds, Monmouth Medical Center, Long Beach, NJ, *“Learning to outsmart lymphoma cells,”* Oct. 7, 2010; University of Colorado, Denver, School of Medicine, Department of Dermatology, Aurora, CO, *“Colorado Dermatology External Reviewer,”* April 27-28, 2011; Chicago Dermatological Society Mtg., Rush University Medical Center, Chicago, IL, *“Learning to Clinically Control the Principal Pivot Point of the Immune System” and 2)”Cellular Eavesdropping to Outflank Cutaneous T Cell Lymphoma (CTCL),”* May 11, 2011; Florida Society of Dermatology and Dermatologic Surgery (FSDDS) 2011 Annual Meeting, Boca Raton, FL, *“Learning to Clinically Control the Principal Pivot Point of the Immune System” and “Cellular Eavesdropping to Outflank Cutaneous T Cell Lymphoma,”* May 28-29, 2011; Bridgeport Hospital Medical Gd. Rds., *“Immunologic Jiu-Jitsu – Turning the Power of the Immune System into an Ally Against Cancer and Auto-Immunity,”*December 15, 2011; Buffalo/Rochester Dermatologic (BDR) Mtg., *“Learning to immunize against cancer,”* September 18, 2012; University of North Carolina Gd. Rds., *“*University of Washington, HEME Oncology Grand Rounds Speaker, *e George Crane Jr Lecture: Cutaneous T Cell Lymphomas,”* October 12, 2012; Mayo Clinic Rochester Dermatology Department Grand Rounds, *“Striving to Therapeutically Master the T Cell Master Switch: Tuning Dendritic Antigen Presenting Cells,”* May 23, 2013; ‘Clinical Trials of Dendritic Cell Therapies for Cancer: Biotech’s Bumpy Road to the Market’ symposium at the New York Academy of Sciences, “*Cellular Immunotherapy for T Cell Lymphoma: Advantages of Maturationally Synchronized, Physiologically Induced Dendritic Cells,”* Oct. 28, 2013; Univ. of Cincinnati College of Medicine, *“Anti-Cancer Immunotherapeutic Lessons Learned from Management of Cutaneous T Cell Lymphoma,”* Nov. 14, 2013; Massachusetts General Hospital, Boston MA, *“Dermatology Department External Reviewer,”* Jan. 9-10, 2014; ASFA & WAA Joint Conference, “Cracking ECP’s Mechanistic Dode: Immunotherapeutic Potential of Tunable Dendritic Cells,” April 5, 2014; Heidi and Scott Schuster and the Brigham and Women’s Hospital Department of Dermatology, 4th Annual Harley A. Haynes Lectureship and Symposium, *“Cutaneous T-Cell Lymphoma: Partnering with Patients to Beat the Cancer,”* April 24, 2014; Ann & Robert H. Lurie Children’s Hospital, Northwestern University Feinberg School of Medicine, *“Physiologic Triggering of Dendritic Cell Maturation and Function: The Bidirectional Mechanism Underlying ECP’s Immunotherapeutic Efficacy,”* May 28, 2014; Annual Katie Rodan and Kathy Fields Lecture, Stanford University School of Medicine, Department of Dermatology, *“Steps towards Partnering with the Immunologic Master Switch for Clinical Management of Cancer and Transplant Rejection,”* Oct. 30, 2014; Fellowship Program in Transfusion Medicine Grand Rounds, Harvard School of Medicine, *“Physiologically Induced Dendritic Cells,”* Nov. 12, 2014; Society for Investigative Dermatology Annual Mtg. / Translational Science Symposium on Immune Therapies in Skin Cancer, *Immunizing Against Patient-Specific CTCL Antigens,”* May 6, 2015; E.P. Cawley Memorial Lecture Series, University of Virginia School of Medicine, May 21, 2015; New York Cardiac Lecture-Health Conference, September 26, 2015; Manhattan (Held at the Lotos Club), *“Advances in Cancer Immunotherapy,”* February 9, 2016; Essentials ad Advances in Apheresis Therapies Conference, *“Modifying T-cell Biology: The ECP Story”* March 4, 2016; University of Washington, UW School of Medicine, Hematology Grand Rounds, *Using Physiologic OC to Immunize Against Cancer”* June 17, 2016; 80th Annual Meeting of the Eastern Division of Japanese Dermatological Association, Hamamatsu, Japan, “*Physiologically Partnering with the Immune System to Produce Selective Anti-Cancer Immunity*.” October 29, 2016; Boston University School of Medicine, Howard Koh Visiting Professorship Grand Rounds Lecture, “*Elucidation of ECP Mechanistic code: Scientific Principles & Practical Implications for Cancer Immunotherapy & Immunoregulation,* April 5, 2017; American Council of ECP, Manhattan, (Held at the Lotos Club), *“ECP’s Organizing Principle – Physiologic Production of Tunable Regulatory Dendritic Cells,”* April 13, 2017; American Society for Apheresis (ASFA) Scientific Symposium Annual Meeting “*Elucidation of the ECP Mechanistic code: Scientific Principles & Practical Implications for Cancer Immunotherapy”* May 3, 2017; Comprehensive Review of John Hopkins Medicine Department of Dermatology, May 12, 2017; New York Cardiac Presentation, June 16, 2017; Therakos National Business Conference, 30 Anniversary of ECP, Dana Point California, September 27, 2017; T-Cell Lymphoma Forum, *Photopheresis The Next Generation Immunotherapy”* February 2, 2018; Manhattan (Held at the Lotos Club), *Making Your Immune System Your Ally”* March 2, 2018; University of Michigan Department of Dermatology, External Reviewer, March 7-8, 2018; Mount Sinai Grand Rounds Visiting Professor Lecturer, “*Therapeutically partnering with the physiologic immune system”* April 26, 2018; AFSA Breakfast with the Experts II; April 27, 2018; Bloodworks Northwest, Seattle, Washington, *“Scientific Presentation”* June 13, 2018; Second American Council for ECP, Portland, Oregon, *“ECP’s Science – Its Ten Empowering Fundamental Elements”* April 14, 2019; American Society for Apheresis, University of Washington, *“Putting the Immune Master Switch in Clinician Hands”* February 24, 2020; United States Cutaneous Lymphoma Consortium Keynote Address, *“Therapeutically Partnering with the Immune System – Clinically Dialing Targets via the Dendritic Cell Switchboard”*March 19, 2020

PUBLICATIONS:

Original Research Reports:

1. Edelson RL, Smith RW, Frank MM and Green I. Identification of subpopulations of mononuclear cells in cutaneous infiltrates: differentiation between B cells, T cells, and histiocytes. J Invest Dermatol 61:82-89, 1973.

2. Edelson RL, Kirkpatrick G, Shevach E, Schein P, Smith R, Green I and Lutzner MA. Preferential cutaneous infiltration by thymus-derived lymphocytes. Ann Intern Med 80: 685-692, 1974.

3. Shevach EM, Edelson RL, Frank MM, Lutzner MA and Green I. A human leukemia cell with both B and T cell surface receptors. Proc Natl Acad Sci 71: 863-866, 1974.

4. Edelson RL, Facktor M, Andrews A, Lutzner MA and Schein P. Successful management of the Sezary syndrome: mobilization and removal of extravascular neoplastic T cells by leukapheresis. New Engl J Med 291: 293-294, 1974.

5. Edelson RL, Lutzner MA, Kirkpatrick CH, Shevach EM and Green I. Morphologic and functional properties of the atypical T lymphocytes of the Sezary syndrome. Mayo Clin Proc 49: 558-566, 1974.

6. Yoshida T, Edelson R, Cohen S and Green I. Migration inhibitory in serum and cell supernatants in patients with Sezary syndrome. J Immunol 114: 914-918, 1975.

7. Gerna-Torsellini M, Edelson RL, Frank MM and Kaplan A. Identification of subpopulations of mononuclear cells in cutaneous infiltrates. II. Urticaria. Bollettino Sieroterapica Milanese 54: 24-30, 1975.

8. Edelson RL, Hearing VJ, Dellon AL, Frank MM, Edelson EK and Green I. Differentiation between B cells and histiocytes in melanocytic lesions: Primary and metastatic melanoma and halo and giant pigmented nevi. Clin Immunol and Immunopath 4: 557-568, 1975.

9. Broder S, Edelson R, Lutzner M, Nelson D, MacDermott R, Durm M, Goldman C, Meade B and Waldman T. The Sezary Syndrome: A malignant proliferation of helper T cells. J Clin Invest 58: 1297-1306, 1976.

10. Dellon L, Edelson R and Chretien P. Defining the malignant potential of giant pigmented nevi. Plastic Reconstr Surg 57: 611-618, 1976.

11. Weng-Peng J, Lutzner M and Edelson R. Cytogenetic studies and clinical implications in patients with Sezary syndrome. Cancer 38: 861-867, 1976.

12. Gerna Tosellini M and Edelson RL. Identificajione delle Cellule Sinformonocitarie degli infiltrati mediante marcatura con eritrociti di montone dei recettori specifici di membrana. Bolletino Della Societa Intaliana di Biologia Sperimentale 51: 917-921, 1976.

13. Edelson RL. Efficacy of leukapheresis procedures in the management of cutaneous T cell lymphoma-leukemic phase. Proceed. of the 4th Advanced Blood Components Seminar 1-7, 1977.

14. Edelson RL, Brown J, Grossman M and Hardy M. Anti-thymocyte globulin in treatment of T cell lymphoma. Lancet II: 1-7, 1977.

15. Edelson RL, Finkelman F, Steinberg A, Ahmed A, Broder S, Strong D and Green I. Reactivity of lupus erythematosus antibodies with leukemic helper T cells. J Invest Dermatol 70: 42-44, 1978.

16. Edelson RL, Berger C, Raafat J and Warburton D. Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. J Invest Derm 73: 548-550, 1979.

17. Schackney S, Edelson R and Bunn P. The kinetics of Sezary cell production. Cancer Treat Rep 63: 659-662, 1979.

18. Berger C and Edelson R. Comparison of lymphocyte function after isolation by ficoll-hypaque flotation or elutriation. J Invest Derm 73: 231-235, 1979.

19. Berger C, Warburton D, Raafat J, LoGerfo P and Edelson R. Cutaneous T cell lymphoma: Neoplasm of T cell with helper activity. Blood 53: 642-650, 1979.

20. Edelson RL, Raafat J, Berger CL, Grossman M, Troyer C and Hardy M. Antithymocyte Globulin in the Management of Cutaneous T Cell Lymphoma. Cancer Treat Rep 63: 675-680, 1979.

21. Rubenfeld MR, Edelson RL, Lofstrom L and Warburton D. Neoplastic human T cells capable of responding to multiple alloantigens. Blood 55: 470-473, 1980.

22. Kung PC, Berger CL, Goldstein G, LoGerfo P and Edelson RL. Cutaneous T cell lymphoma - characterization by monoclonal antibodies. Blood 57: 261-266, 1981.

23. Fithian E, Kung P, Goldstein G, Rubenfeld M, Fenoglio C and Edelson R. Reactivity of Langerhans cells with hybridoma antibody. Proc Natl Acad Sci USA 78: 2541-2544, 1981.

24. Bunn P, Edelson R, Ford S and Shackney S. Patterns of cell proliferation and cell migration in the Sezary syndrome. Blood 57: 452-463, 1981.

25. Rubenfeld MR, Silverstone AE, Knowles DM, Halper JP, DeSostoa A, Fenoglio CM and Edelson RL. Induction of lymphocyte differentiation by epidermal cultures. J Invest Derm 77: 221-224, 1981.

26. DiPietro WP, Berger C, Harber LC and Edelson RL. Normal numbers of phenotypic helper, suppressor, and total T cell populations in psoriasis vulgaris: Quantitation by monoclonal antibodies. J Amer Acad Derm 5: (3): 304-307, 1981.

27. Berger CL, Kung P, Goldstein G, DiPietro W, Takezaki S, Chu A, Fithian E and Edelson RL. Use of orthoclone monoclone antibodies in the study of selected dermatologic conditions. Int J Immunopharmac 3: 275-282, 1981.

28. Fenoglio C, Oster MW, LoGerfo P, Reynolds T, Edelson RL, Patterson JAK, Madeiros E and McDougall JK. Kaposi's sarcoma following chemotherapy for testicular cancer in a homosexual man: Demonstration of cytomegalovirus RNA in sarcoma cells. Human Pathology 13: 955-959, l982.

29. Berger CL, Morrison SL, Chu A, Patterson J, Estabrook A, Takezaki S, Sharon J, Warburton,

Irigoyen O, and Edelson RL. Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigen. J Clin Invest 70: 1205-1210, 1982.

30. Takezaki S, Morrison SL, Berger CL, Kung PC, Chu AC and Edelson RL. Biochemical characterization of a differentiation antigen shared by human epidermal Langerhans cells and cortical thymocytes. J Clin Immunol Vol. 2 (3): 128S-134S, 1982.

31. Chu A, Eisinger M, Lee S, Takezaki S, Kung PC and Edelson RL. Immunoelectron microscopic identification of Langerhans cells using a new antigenic marker. J Invest Derm 78: 177-180, 1982.

32. Chu AC, Goldstein G, Patterson JAK, Berger CL, Takezaki S and Edelson RL. Thymopoietin-like substance in human skin. Lancet Vol. II, No. 8301, pp. 766, 1982.

33. Chu A, Berger CL, Kung PC and Edelson RL. In situ identification of Langerhans cells in the dermal infiltrate of cutaneous T cell lymphoma. J Amer Acad Dermatol 6: 350-354, 1982.

34. Chu A, Patterson JAK, Berger CL and Edelson RL. T cell subpopulations of cutaneous T cell lymphoma (CTCL). J Invest Derm 78: 334, 1982.

35. Chu AC, Goldstein G, Berger CL, Takezaki S, Patterson JAK and Edelson RL. Thymopoietin-like substance in human skin. J Invest Dermatol 81: 194-197, 1983.

36. Estabrook A, Berger CL, LoGerfo P, Hardy M and Edelson RL. Antigenic modulation of T lymphocytes by monoclonal antibodies. Transplant Proc 15: 651, 1983.

37. Estabrook A, Mittler R, LoGerfo P, Edelson RL and Berger CL. Antigenic modulation of pan-T cell and T-cell subset specific markers. Diag Immunol 1: 199-204, 1983.

38. Patterson JAK, Griffiths-Chu S, Berger CL, Edelson RL and Chu AC. Recognition of immature T-cell phenotypes in neonatal blood using monoclonal antibodies. Diag Immunol 1: 205-210, 1983.

39. Chu A, Patterson J, Berger C, Vonderheid E and Edelson RL. In situ study of T-cell subpopulations in cutaneous T cell lymphoma. Cancer 54: 2414-2422, 1984.

40. Griffiths-Chu S, Patterson JAK, Berger CL, Edelson RL and Chu AC. Characterization of immature T cell populations in neonatal blood. Blood 64: 296-300, 1984.

41. Gasparro FP, Berger CL and Edelson RL. Effect of monochromatic UV-A light and 8-methoxypsoralen on human lymphocyte response to mitogen. Photodermatology 1: 10-17, 1984.

42. Patterson JAK, Haynes BF, Eisinger M, Berger CL and Edelson RL. Monoclonal antibody reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative states. J Invest Derm 83 (3): 210-213, 1984.

43. Gasparro FP, Saffran WA, Cantor CR and Edelson RL. Wavelength dependence for AMT crosslinking of pBR322 DNA. Photochem and Photobiol 40: 215-219, 1984.

44. Murphy RF, Bisaccia E, Cantor RC, Berger CL and Edelson RL. Internalization and acidification of insulin by activated human lymphocytes. J Cell Physiol 121 (2): 351-356, 1984.

45. Berger CL, Cantor C, Welsh J, Dervan P, Begley T, Grant S, Gasparro FP and Edelson RL. Comparison of synthetic psoralen derivatives and 8MOP in the inhibition of lymphocyte proliferation. The medical and biological effects of light. Ann NY Acad Sci 454: 80-90, 1985.

46. Edelson RL and Fink J. Immunologic function of skin. Scientific American 252: 46-53, 1985.

47. Santella RP, Dharmaraja N, Gasparro FP and Edelson RL. Monoclonal antibodies that recognize 8-MOP modified DNA. Nucleic Acid Res 13: 2533-2544, 1985.

48. Kaudewitz P, Kind P, Burg G, Rieber P, Berger C, Edelson R and Braun-Falco O. Longitudinal study of surface antigen pattern in cutaneous T-cell lymphomas. Proc of the European Congress on Immunohistology. Cambridge University Press, 123-124, 1985.

49. Yemul SS, Berger C, Estabrook A, Edelson R and Bayley H. The delivery of phototoxic drugs to selected cells. NY Acad Sci 446: 403-414, 1985.

50. Gasparro FP, Bagel J and Edelson RL. HPLC analysis of 8-MOP photoadducts in calf thymus DNA, poly (dAdT.dAdT), poly(dA.dT) and poly(dT). Photochem Photobiol 42: 98-101, 1985.

51. Gasparro FP, Chan G and Edelson RL. Phototherapy and photopharmacology. Yale J Biol and Med 58: 519-534, 1985.

52. Berger CL, Friedman-Kien AE, DiFranco M, Rehle T, Ostreicher R, Knobler R, Donofrio S, Laubenstein L and Edelson RL. Common membrane antigen on lymphocytes from cutaneous T cell lymphoma and acquired immune deficiency syndrome patients recognized by monoclonal antibody BE2. J Invest Derm 87: 280-283, 1986.

53. Gasparro FP, Yemul SS, Knobler RM and Edelson RL. Receptor mediated photocytotoxicity. Synthesis of a photoactivatable psoralen derivative conjugated to insulin. Biochem Biophys Res Comm. 141: 502-509, 1986.

54. Gasparro FP, Song J, Knobler RM and Edelson RL. Quantitation of psoralen photoadducts in DNA isolated from lymphocytes treated with 8-methoxypsoralen and ultraviolet A light (Extracorporeal Photopheresis) in Current Problems in Dermatology 15: 67-84, 1986.

55. Edelson RL, Berger CL, Gasparro F, Jegasothy B, Heald PW, Wintroub B, Vonderheid E, Knobler R, Wolffe K, Plewig G, McKiernan G, Christensen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G and Laroche L. Treatment of Cutaneous T Cell Lymphoma by Extracorporeal Photochemotherapy. New Eng J Med 316: 297-303, 1987.

56. Yemul S, Berger C, Estabrook A, Suarez S, Edelson R and Bayley H. Selective killing of T lymphocytes by phototoxic liposomes. Proc Natl Acad Sci 84: 246-250, 1987.

57. Bayley H, Gasparro FP and Edelson RL. Photoactivatable drugs. Trends in Pharmacological Sciences 8: 138-143, 1987.

58. Heald PW and Edelson RL. New therapies for cutaneous T cell lymphoma. Arch Derm 123: 189-191, 1987.

59. Knobler RM, Rehle T, Grossman M, Saxinger CW, Berger CL, Oster M, McKiernan G and Edelson RL. Clinical evolution of cutaneous T cell lymphoma in a patient with antibodies to human T-lymphotrophic virus Type I. J Amer Acad Derm 17: 903-909, 1987.

60. Warburton D, Shapiro P, Berger C and Edelson RL. Clonal chromosomal abnormalities in cutaneous T cell lymphoma. Cancer Genet Cytogenet 28: 267-276, 1987.

61. Chu T, Berger C, Morris J and Edelson RL. Induction of an immature T cell phenotype in malignant helper T cells by co-cultivation with epidermal cell cultures. J Invest Derm 89: 358-361, 1987.

62. Gasparro FP, Knobler RM, Weingold DH, Yemul SS and Edelson RL. Photoactivation of a psoralen derivative conjugated to insulin. Ann NY Acad Science Vol. 507, p. 339-340, 1987.

63. Longley BJ, Braverman IM, Edelson RL. The skin as an immunologic organ. Ann NY Acad Sci, 548: 225-232, 1988.

64. Edelson RL. Light-activated Drugs. Scientific American 259: 68-75, 1988.

65. Berger CL, Eisenberg A, Soper L, Chow J, Simone J, Gapas Y, Cacciapaglia B, Bennett L, Edelson RL, Warburton D and Benn P. Dual genotype in cutaneous T cell lymphoma: Immunoglobulin gene rearrangement in clonal T cell malignancy. J Invest Derm 90: 73-77, 1988.

66. Saffran WA, Welsh J, Gasparro FP, Knobler RM, Cantor CR and Edelson RL. Synthesis and characterization of a biotinylated psoralen. Nucleic Acids Res 16: 7221-7321, 1988.

67. Gasparro FP, Battista J, Song J and Edelson RL. Rapid and sensitive analysis of 8-methoxypsoralen in plasma. J Invest Dermatol 90:234-236, 1988.

68. Gasparro FP, Knobler RM, Saffran WA and Edelson RL. Photochemistry of Gilvocarcin: An Anti-tumor Antibiotic. Chem Biol Interactions 67: 267-274, 1988.

69. Longley J, Kraus J, Alonso M, Edelson RL. Molecular cloning of CD1a (T6), A Human epidermal Dendritic Cell Marker Related to Class I MHC Molecules. J Invest Derm, 92: 628-631, 1989.

70. Perez MI, Edelson RL, Laroche LL and Berger CL. Inhibition of anti-skin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Derm 92: 669-676, 1989.

71. Heald P, Perez M, McKiernan G, Christensen I, Edelson R. Extracorporeal photochemotherapy: Indications, methodology, safety aspects, side effects and long-term results. Photodermatology 6:171, 1989.

72. Edelson RL. Photopheresis: A new therapeutic concept.. The Yale J Bio and Med, 62, 6, Nov-Dec, pp. 565-578, 1989.

73. Perez MI, Edelson RL, John L, Laroche L and Berger CL. Inhibition of Antiskin allograft immunity induced by infusions with Photoactivated Effector T lymphocytes (PET cells). The Yale J Biol and Med, 62: 595-609, 1989.

74. Edelson R. Photopheresis. Jour Clin Apheresis. 5:77-79, 1990.

75. Gasparro FP, Dall'Amico R, O'Malley M, Heald PW, Edelson RL. Cell Membrane DNA: A New Target for Psoralen Photoadduct Formation. Photochem Photobiol 52: 315-321, 1990.

76. Berger CL, Perez M, Laroche L, Edelson R. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. J Invest Derm 94, 52-57, 1990.

77. Heald PW, Berger CL, Yamamura T, McNamara J, Edelson RL. BE-2 Antigen: Appearance during T cell activation and increase with stimulation and growth of T cells. J Invest Derm 94: 452-455, 1990.

78. Heald PW, Perez MI, McKiernan G, Christensen I, Edelson RL. Extracorporeal Photochemotherapy for CTCL. Apheresis, pg. 443-447, 1990.

79. Rook A, Jegasothy B, Heald P, Nahass G, Ditre C, Witmer W, Lazarus G, Edelson RL: Extracorporeal photochemotherapy for drug resistant pemphigus. Ann Int Med Feb 15, 112:303-305, 1990.

80. Heald P, Perez M, Christensen I, McKiernan G, Edelson R: Treatment of cutaneous T-cell lymphoma: The Yale-New Haven Hospital experience. Yale J Biol Med 62:629-638, 1990.

81. Edelson RL. Photopheresis - Present and Future Aspects. News & Views Section. J Photochem Photobiol. 10: 165-174, 1991.

82. Tokura Y, Edelson RL, Gasparro FP. Formation and Removal of 8-MOP-DNA photoadducts in keratinocytes: Effects of calcium concentration and retinoids. J Invest Derm 96: 942-949, 1991.

83. Bevilacqua PM, Edelson RL, Gasparro FP. HPLC Analysis of 8-Methoxypsoralen Monoadducts and Crosslinks in Lymphocytes and Keratinocytes. J Invest Derm 97: 151-155, 1991.

84. Edelson RL. Photopheresis: a Clinically Relevant Immunobiologic Response Modifier. Ann Am Acad Sci 636: 154-164, 1991.

85. Malawista SE, Trock D, and Edelson RL. Photopheresis for Rheumatoid Arthritis. Ann Am Acad Sci 636: 217-226, 1991.

86. Tokura Y, Yagi J, Edelson RL, Gasparro FP. Inhibitory effect of 8-MOP plus UVA on IL-1 production by murine epidermal keratinocytes. Photochem Photobiol 53: 517-523, 1991.

87. Gasparro FP, Edelson RL, O'Malley ME, Ugent SJ, Wong HH. Photoactivatable Antisense DNA: Suppression of Ampicillin Resistance in Normally Resistant Escherichia coli. Antisense Res & Dev, 1: 117-140, 1991.

88. Heald P, Edelson R: The immunobiology of cutaneous T-cell lymphoma. J Nat Cancer Inst 83: 400, 1991.

89. Malawista SE, Trock DH, Edelson RL. A Pilot Study. Treatment of Rheumatoid Arthritis by extracorporeal photochemotherapy. Arthritis and Rheumatism, 34:6, 646-654, 1991.

90. Perez MI, Berger CL, Yamane Y, John L, Laroche L, Edelson RL. Inhibition of Antiskin Allograft Immunity Induced by infusions with photoinactivated effector T lymphocytes (PET cells). The Congenic Model. Transplantation 51: 1283-1289, 1991

91. Yamane Y, Perez MI, Edelson R, Agostino N, Pernis B. Endocytosis of the TCR, CD3 Complex and Class-I major histocompatibility antigens in a human T cell line. Cellular Immunology 136: 496-503, 1991.

92. Perez MI, Lobo F, Yamane Y, John L. Berger CL, Edelson RL, Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T cell lymphocytes (PET cells). Is in vivo cell transferable? Annals NY Acad Sci 636:95-112, 1991.

93. Yamane Y, Perez MI, John L, Edelson R. Effect of prednisolone and cyclophosphamide on inhibition of the response to alloantigen induced by treatment with photoinactivated effectors T cells (PET cells). Annals NY Acad Sci 636:406-408, 1991.

94. Laroche L, Edelson RL, Perez MI, Berger C. Antigen-specific tolerance induced by autoimmunization with photoinactivated syngeneic effector cells. Annals NY Acad Sci 636:113-123, 1991.

95. Berger CL, Edelson RL, Edwards N, Sanchez J, Coppey L, He X, Marboe C, Rose E. Autoregulation of the Immune Response in Autoimmune Disease and Cardiac Transplantation by Photoinactivated Autologous Lymphocytes. Annals NY Acad Sci 636: 266-278, 1991.

96. Ding TG, Qiu BS, Kolenik SA, Yan SL, Longley BJ, Edelson RL. In situ transcription and detection of CD1a mRNA in human skin. J Chinese Medicine 71(1: 6-8, 1991).

97. Ding TG, Qiu BS, Kolenik SA, Yan SL, Wang XM, Longley BJ, Edelson RL. Effect of interleukin-1, tumor necrosis factor and granulocyte macrophage-colony stimulating factor on CD1a expression by human epidermal Langerhans cells. J Chinese Dermatology 24(4): 219-221, 1991.

98. Ding TG, Yan SL, Kolenik SA, Wang XM, Qiu BS, Longley BJ, Edelson RL. Expression of transfected CD1a: Development of an immunophenotypic model of human epidermal Langerhans cells in vitro. J Chinese Dermatology 24(6): 401-404, 1991.

99. Tokura Y, Heald PW, Yan SL, Edelson RL. Stimulation of Cutaneous T-cell Lymphoma Cells with Superantigenic Staphylococcal Toxins. J Invest Dermatol 98: 33-37, 1992

100. Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, Rietschel RL, Wintroub B, Kahaleh MB, Varga J, Heald PW, Steen V, Massa MC, Murphy GF, Perniciaro C, Istfan M, Ballas SK, Edelson RL. Treatment of Systemic Sclerosis with Extracorporeal Photochemotherapy: Results of a Multicenter Trial. Arch Derm 128: 337-346, 1992.

101. Heald P, Buckley P, Gilliam A, Perez M. Knobler R, Kacinski B, Edelson R. Correlations of Unique Clinical Immunotypic, and Histologic findings in Cutaneous Gamma/Delta T-Cell. J Amer Acad Derm 26: 865-870, 1992.

102. Perez, MI, Yamane Y, John L, Gasparro FP, Edelson RL. DNA associated with the cell membrane is involved in the inhibition of the skin rejection response induced by infusions of photodamaged alloreactive cells that mediate rejection of skin allograft. Photochem Photobiol 55: 839-849, 1992.

103. Tokura Y, Edelson RL, Gasparro FP. Retinoid augmentation of bioactive interleukin-1 production by murine keratinocytes. British Jrnl Derm 126: 485-495, 1992.

104. Yamane Y, Lobo FM, John LA, Edelson RL, Perez MI. Suppression of anti-skin-allograft response by photodamaged effector cells-the modulating effects of prednisolone and cyclophosphamide. Transplantation 54: 119-124 1992.

105. Heald P, Rook A, Perez M, Wintroub B, Knobler R, Jegasothy B, Gasparro F, Berger C, Edelson R. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Derm 27 (3):427-433, 1992.

106. Kono DW, Baccala R, Balderas RS, Kovac SJ, Heald PW, Edelson RL, Theofilopoulos AN. Application of a multiprobe RNase protection assay and junctional sequences to define V gene diversity in Sezary syndrome. Am J Path 140:823-830, 1992.

107. Perez M, Lobo F, John L, Edelson RL. Induction of a cell-transferable suppression of alloreactivity by photodamaged lymphocytes. Transplantation 54:896-903,1992.

108. Ding TG, Qiu BS, Kolenik SA, Yan SL, Wang XM, Longley BJ, Edelson RL. Effect of granulocyte macrophage colony-stimulating factor on mixed lymphocyte-epidermal cell culture. J Chinese Dermatology 25(2): 88-90, 1992.

109. Heald PW, Yan SL, Edelson RL, Tigelaar R, Picker LJ. Skin-Selective Lymphocyte Homing Mechanisms in the Pathogenesis of Leukemic Cutaneous T-Cell Lymphoma. J Invest Dermatol 101:222-26, 1993.

110. Frieden TR, Bia FJ, Heald PW, Eisen RN, Patterson TF, and Edelson RL. Cutaneous cryptococcoses in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate. Clin. Inf. Dis. 17:776-778, 1993.

111. Tokura Y, Edelson RL, Gasparro FP. Modulation of 8-Methoxypsoralen-DNA Photoadduct Formation by Cell differentiation, mitogenic stimulation and phorbol ester exposure in murine T lymphocytes. Photochem and Photobiol. 58:6: 822-826, 1993.

112. Perez MI, Edelson RL. Regulation of Immunity by Ultraviolet Radiation and Photosensitized Reactions. Chemical Immun 58: 314-330, 1994.

113. Tokura Y, Yagi J, O'Malley M, Lewis JM, Takigawa M, Edelson RL and Tigelaar RE. Superantigenic Staphylococcal Exotoxins Induce T-Cell Proliferation in the presence of Langerhans Cells or Class II-Bearing keratinocytes and stimulate keratinocytes to produce T-cell-activating cytokines. J Invest Dermatol 102: 31-38, 1994.

114. Edelson RL, Perez M, Heald P, Berger C. Extracorporeal Photochemotherapy. Biologic Therapy of Cancer, J.B. Lippincott Co., V. DeVita, S. Hellman, S. Rosenberg, Editors. 4(5),:1-12, 1994.

115. Schmitt IM, Maxwell VM, Olack GA, Edelson RL, Chimenti S, Gasparro FP. The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. J Photochem and Photobiol B: Biol., 22: 17-21, 1994.

116. Heald P, Yan SL, Latkowski J, Edelson R. Deficiency in normal and circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 130:198-203, 1994.

117. Longley J, Tyrrell L, Lu, S-Z, Farrell J, Ding T, Yan S, Sallee D, Heald P, Berger C, Tigelaar R, Edelson R. Malignant and Normal T Cells Show Random Use of T-cell Receptor Chain Variable Regions in Patients with Cutaneous T-cell Lymphoma. J Invest Dermatol 105:62-64, 1995.

118. Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman AM, Kacinski BM. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Rad Oncol 32:987-995, 1995.

119. Heald PW, Kim HY, Perez M, Edelson R, Berger CL. T-cell responses in Photoimmune therapy. J Clin Apheresis, 10:144-149, 1995.

120. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL. The immune response to class I associated tumor-specific cutaneous T cell lymphoma antigens. J Invest Dermatol 107:392-397, 1996.

121. Wilson LD, Quiros PA, Kolenik SA, Heald PW, Braverman IM, Edelson RL & Kacinski BM. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Amer Acad Derm 35: 69-73, 1996.

122. Quiros PA, Jones GW, Kacinski BM, Braverman IM, Heald PW, Edelson RL, Wilson LD. Total Skin Electron Beam Therapy Followed by Adjuvant Psoralen / Ultraviolet-A Light in the Management of Patients with T1 and T2 Cutaneous T-Cell Lymphoma (Mycosis Fungoides). Int J Radiation Oncology Biol Phy 38: 1027-1035, 1997.

123. Imaeda S, Felli A, Schmitt I, Chimenti S, and Edelson RL. Induction of Functional Empty Class I Major Histocompatibility Complex Glycoproteins by Photoactivated 8-Methoxypsoralen. J Invest Dermatol 107:887-890, 1996.

124. Fargnoli MC, Edelson RL, Berger CL, Chimenti S, Couture C, Mustelin T, Halaban R. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk. Leukemia 11: 1338-1346, 1997.

125. Berger CL, Dong Z, Hanlon D, Bisaccia E and Edelson RL. A Lymphocyte Cell Surface heat shock protein homologous to the endoplasmic reticulum chaperone, immunoglobulin heavy chain binding protein BIP. Int J Cancer: 71: 1077-1085, 1997.

126. Hanlon D, Berger C, and Edelson RL. Photoactivated 8-Methoxypsoralen Treatment Causes a Peptide-Dependent Increase in Antigen Display by Transformed Lymphocytes. Int J of Cancer, 78: 70-75, 1998.

127. Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL. Tumor-Specific Peptides in Cutaneous T Cell Lymphoma: Association with Class I Major Histocompatibility Complex and Possible Derivation from the Clonotypic T Cell Receptor. Int J of Cancer, 76: 304-311, 1998.

128. Edelson RL. Cutaneous T-Cell Lymphoma: A Model for Selective Immunotherapy. The Cancer Journal *from Scientific American.* Volume 4 (2): 62-71, 1998.

129. Schechner JS, Edelson RL, McNiff JM, Heald PW, Pober JS. Expression of Integrin 4 7 on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis. Lab Invest 79: 601-607, 1999.

130. Heald PW and Edelson RL. Cutaneous T Cell Lymphoma. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 138-145, 1999.

131. Edelson RL and Berger C. Extracorporeal photochemotherapy. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers Limited, London, England, pp. 396-408, 1999.

132. Edelson, Richard L. Pemphigus - Decoding the Cellular Language of Cutaneous Autoimmunity. Editorial New Engl J Med, 343: 60-61, 2000.

133. Girardi M. Edelson RL. Cutaneous T-Cell Lymphoma: Pathogenesis and Treatment. Oncology 14:7 1061-1069, 2000.

1. Jillilla AP, Murren JR, Hamid KK, Longley BJ, Edelson RL, Cooper DL. P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest. 18(7): 609-13, 2000.
2. Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, and Edelson RL. Induction of Human Tumor-Loaded Dendritic Cells. Int J Cancer 91: 438-447, 2001.

136. Edelson RL. The Helping Hand of Dendritic Cells. Annals of the NY Acad Sci. Vol. 941: 1, 2001.

137. Meech SJ, Edelson R, Walsh P, Norris DA and Duke RC. Reversible Resistance to Apoptosis in Cutaneous T Cell Lymphoma. Annals of the NY Acad Sci., Vol. 941: 46-58, 2001.

138. Berger CL, Longley J, Hanlon D, Girardi M and Edelson R. The Clonotypic T Cell Receptor is a Source of Tumor-associated Antigens in Cutaneous T Cell Lymphoma. Annals of the NY Acad Sci., Vol. 941: 106-122, 2001.

139. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, Christensen I, Howe G, Crouch J, El-Fishawy P, Edelson R. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood, Vol.99: 8-2929-2939, 2002.

140. Edelson RL. Editorial. Transimmunization: the science catches up to the clinical success. Transfusion and Apheresis Science, 26: 177-180, 2002.

141. Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion and Apheresis Science, 26: 205-216, 2002.

1. Girardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of dendritic Antigen Presenting Cells by Transimmunization. Technology in Cancer Research and Treatment. 1:1: 65-69, 2002.
2. Berger CL, Edelson RL. Current Concepts of the Immunobiology and Immunotherapy of Cutaneous T Cell Lymphoma: Insights Gained through Cross-talk between the Clinic and the Bench. Leukemia & Lymphoma. 44(10): pp. 1697-1703, 2003.
3. Girardi, M, Knobler R, Edelson R. Selective immunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics of North America, 17/6, p. 1391-1401, 2003.
4. Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russell-Jones R. CD30+ Cutaneous Lymphoma in Association with Atopic Eczema. Arch Dermatol. 140: 449-454, 2004.
5. Berger CL and Edelson R. The Life Cycle of Cutaneous T Cell Lymphoma Reveals Opportunities for Targeted Drug Therapy. In *Current Cancer Drug Targets*. 4:609-619, 2004.
6. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL. Cutaneous T cell

lymphoma, malignant proliferation of T-regulatory cells. Blood. 105:1640-1647, 2004.

148. Salskov-Iversen M, Berger CL, Edelson RL. Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading. J Immune Based Therapies and Vaccines. 3:4, 2005.

1. Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock C, Berger CL, Edelson RL, Lim HW. Increased Expression of CTLA-4 in PBMC and Malignant T-Cells from Patients with Mycocis Fungoides (CTCL). J. Invest Dermatol 126:212-219, 2006.
2. Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M. Gudipati L, Shang M, Showe MK, Showe LC. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5 to 99% circulating tumor cells with 90% accuracy. Blood 107: 3189-3196, 2006
3. Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk Lymph 47:1495-1503, 2006.
4. Berger CL, Vasquez JG, Shofner J, Mariwalla K, Edelson RL. Langerhans cells: Mediators of immunity and tolerance. Int J Biochemistry & Cell Biol 38:1632-1636, 2006.
5. Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. Mol Imaging Biol 10.1007/s11307-007-1027-y. 2007.
6. Shen X, Berger CL, Tigelaar R, Edelson RL. Development of Immunogenic Tumor-Loaded Dendritic Cells Through Physical Perturbation and Apoptotic Cell Loading. Immuno Invest 37:798-321, 2008.
7. Mutyambizi K, Berger CL, Edelson RL. The balance between immunity and tolerance: the role of Langerhans cells. Cell Mol Life Sci. 2009 Mar;66(5):831-40.
8. Edelson RL. Outsmarting cutaneous t-cell lymphoma cells by decoding the language they speak: focusing past and present insights on future prospects. Clin Lymphoma Myeloma Leuk. Vol. 10, Supp 2, 2010 Sep 1;10-S59-62.
9. Berger CL, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson RL. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 116:4838-4847, 2010.
10. Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, Birchall MA, Hanlon DJ. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine. 2011 Feb;7(1):1-10.
11. Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, Mor G. Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen. Am J Reprod Immunol. 65:597-609, 2011.
12. Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Berger CL, Edelson, RL, Girardi M. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J Invest Dermatol. 2012 Jan; 132(1): 188-97.
13. Prasad S, Cody V, Saucier-Sawyer JK, Fadel TR, Edelson RL, Birchall MA, Hanlon DJ. Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles. Pharm Res. 2012 Sep;29(9):3565-77.
14. Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: Efficient induction of monocyte-to-dendritic cell maturation. Transfus Apher Sci. 2014 Jun;50(3):322-9. doi: 10.1016/j.transci.2013.07.031. Epub 2013 Aug 8. Review.

Transfus Apher Sci. 2013 Aug 8(13):00258-9.

1. Futterleib JS, Feng H, Tigelaar RE, Choi J, Edelson RL. Activation of GILZ gene by photoactivated 8-methoxypsoralen: Potential role of mmunoregulatory dendritic cells in extracorporeal photochemotherapy. Transfus Apher Sci. 2014 Jun;50(3):379-87. doi: 10.1016/j.transci.2013.10.003. Epub 2013 Oct 24 Transfus Apher Sci. 2013 Oct 24.
2. Gonzalez AL, Berger CL, Remington J, Girardi M, Tigelaar RE, Edelson RL. Integrin driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clin Exp Immunol. 2013 Nov 5.
3. Durazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL. Induction of monocyte-to-dendritic cell maturation by exptracorporeal photochemotherapy: Initiation via direct platelet signaling. Transfus Apher Sci. 2013 Nov 28.
4. Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, Tigelaar R, Fahmy TM, Edelson RL. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int J Nanomedicine. 2014 Nov 12;9: -5231-46
5. Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, Levine JE, Morgan S, Schneiderman J, Sloan S, Wu Y, Szczepiorkowski ZM, Cooling L. National Institutes of Health – State of the Science Symposium in Therapeutic Apheresis – Scientific Opportunities in Extracorporeal Photopheresis. Transfus Med Rev. 2015 Jan;29(1):62-70.
6. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic Landscape of cutaneous T cell Lymphoma. Nat Genet. 2015 Sep;47(9):1011-9. doi:10.1038/ng.3356. Epub 2015 Jul 20.
7. Hong E, Usiskin IM, Bergamaschi C, Hanlon DJ,Edelson RL**,** Justesen S, Pavlakis GN, Flavell RA, Fahmy TM. Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity. J Biol Chem. 291:8931-50, 2016.
8. Kibbi N, Sobolev O. Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfus Apher Sci. 2016 Aug;55(1):146-52. doi: 10.1016/j.transci.2016.06.001. Epub 2016 Jun 6.
9. KibbiN, HongE, EzaldeinH, HanlonD, FahmyT, EdelsonR. Quantifying in vivo murine antigen-specific T cell responses without requirement for prior knowledge of antigen identity. Transfus Apher Sci. 56:179-189, 2016.

173. Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer Immunity. Cancer Res. 78:4045-

4058, 2018.

173. Edelson, R, Wu, Y, Schneiderman J. American council on ECP (ACE): Why now? J Cin Aphere. 2018 Aug;33(4): 464-4689.

174. Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D. Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. J Vis Exp. 147, 2019 May 17.

175. Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A,

Rivera, Molina, F, Arshad N, Edelson, RL and Galluzzi L, Open Access Cell Death & Disease. 2019 Aug 2;10(8):578.

176. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, **Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.** J Immunother Cancer 2020 Mar;8(1)

177. Wei BM, Hanlon D, Khalil D, Han P, Tatsuno K, Sobolev O, Edelson RL,

**Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions.** Yale J Biol Med 2020 Mar;93(1):145-159

178. Alvero A, Hanlon D (authors contributed equally), Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Edelson RL, and Mor G. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. OncoImmunology, 2020 May 13;9(1):1758869.

179. Han P and Hanlon D (authors contributed equally), Arshad N, Lee JS, Tatsuno K, Robinson E,

Filler R, Sobolev O, Cote C, Rivera-Molina, F, Toomre D, and Fahmy T, and Edelson R

(co-contributing authors). Platelet P-selectin initiates cross-presentation and dendritic cell

differentiation in blood monocytes. Science Advances 2020; Mar 6(11).

# Review Articles and Chapters

1. Smith RW, Blaese RM, Hatchcock KS, Buell DN, Edelson RL and Lutzner MA. T and B lymphocyte markers in lymphoid cell research and in human diseases in Lymphocyte Recognition and Effector Mechanisms: Proceedings of the Eighth Leukocyte Culture Conference. Academic Press (New York), pages 127-132, 1974.

2. Lutzner MA, Edelson RL and Schein P. Sezary syndrome (chapter) In: Current Dermatologic Management. C. V. Mosby pp. 286-287, 1975.

3. Green I, Jaffe E, Shevach E, Edelson R, Frank M and Berard C: Determination of the origin of malignant reticular cells by the use of surface markers. Monograph - International Academy of Pathology - The Reticuloendothelial System, pages 282-300, 1975.

4. Edelson RL. Membrane properties of the abnormal cells of cutaneous T cell lymphomas. In: Annals Intern Med; 83: 536-542, 1975.

5. Edelson RL. Cutaneous T cell lymphomas - perspective. Annals Intern Med; 83: 548-552, 1975.

6. Edelson R. Cutaneous T cell lymphomas: Clues of a skin-thymus interaction. J Invest Derm; 67: 419-424, 1976.

7. Edelson R. Membrane markers of lymphocytes in cutaneous lymphomas, melanomas and systemic lupus erythematosus. Int J Derm; 15: 557-586, 1976.

8. Schein P, McDonald J and Edelson R. Cutaneous T cell lymphomas. Cancer 38: 1859-1861, 1976.

9. Edelson RL. Recent advances in the cutaneous T cell lymphomas. Cancer Bulletin 64: 209-244, 1977.

10. Lutzner M and Edelson R. Cellular identities in lymphomas. In: Dermatology in General Medicine, editors Fitzpatrick et al, McGraw-Hill Publishers, 1979.

11. Edelson RL. Cutaneous T cell lymphoma. In: Dermatology Update, Elsevier Press, New York, edited by S. Moschella, pp. 195-207, 1979.

12. Edelson R. Cutaneous T cell lymphoma (mycosis fungoides, Sezary syndrome and other variants). J Amer Acad Derm 2: 89-106, 1980.

13. Edelson R. Round cells of the epidermis. J Invest Derm 75: 96-102, 1980.

14. Edelson RL. Cutaneous T-cell lymphoma. J Dermatol Surg Oncol 6: 358-368, 1980.

15. Edelson RL. Other experimental observations. J Dermatol Surg Oncol 6: 388-389, 1980.

16. Gupta S, Safai B, Edelson R, Parrott D and Good R. Locomotion of T-cells from patients with cutaneous T-cell lymphoma. (Sezary syndrome and mycosis fungoides). Cell Immunol 50: 195-201, 1980.

17. Edelson RL. The immunology of lymphoreticular malignancies of the skin. In Progress in Cutaneous Diseases, Fleischmajer R (ed)., Grune & Stratton Publishers, 1981).

18. Edelson RL. Cutaneous T cell lymphoma, leukemic phase. In Clinical Dermatology, Demis et al editors, Harper & Row Publishers, 1981.

19. Edelson RL, Chu A, Takezaki S and Berger CL. The interaction of T-lymphocytes with epidermis. Prog In Dis of Skin, Vol. I, 177-188, 1981.

20. Edelson RL, Berger CL and Armstrong RB. Lymphopheresis in the treatment of the leukemic phase of cutaneous T-cell lymphoma and pemphigus vulgaris. In Nemo GJ and Taswell H (eds): Proc Workshop on Therapeutic Plasmapheresis and Cytapheresis, NIH PUBL. No. 2-1665, pp. 55-71. Rochester: U.S. Dept. Health and Human Services, 1981.

21. Berger CL and Edelson RL. Monoclonal antibodies: Powerful new tools for the clinician. Arch Dermatol, Vol. 118: 627-629, 1982.

22. Patterson JAK and Edelson RL. Cutaneous T cell lymphoma. Med Clin of N Amer, Vol. 66 (4): 895-913, 1982.

23. Patterson JAK and Edelson RL. Interaction of T cells with the epidermis. Brit J Derm 107: 117-122, 1982.

24. Chu A, Berger CL, Lynfield Y, Esseesse I and Edelson RL. Pathogenesis of cutaneous T cell lymphoma. In M. Goos and E. Christophers (eds): Lymphoproliferative Diseases of the Skin, pp. 57-64, 1982.

25. Heald PW, Edelson RL. Leukemic phase of cutaneous T-cell lymphoma. In: Clinical Dermatology, Vol. 4., CD93, 20-12, 1982.

26. Chu A and Edelson RL. Introduction to tumors of the lymphoreticular system. In: Clinical Dermatology, Vol. 4. Harper and Row, Philadelphia, 1982.

27. Berger CL, Edelson RL, Gasparro FP and Harber LC. Skin-associated lymphoid tissues and photo-diseases, theoretical considerations, in Krueger J and Daynes R (eds): Clinical Photoimmunology, CRC Press, 1983.

28. Berger CL, Chu A, Fithian E, Patterson J and Edelson RL. Monoclonal antibodies used for tissue diagnosis in situ and in the circulation of patients with a variety of dermatologic conditions. Amer J Dermatopath 5: 85, 1983.

29. Berger CL and Edelson RL. Networks of Immunity: Functions of the immune system. In: Cutaneous Toxicity, V.A. Drill and P. Lazar (eds), Raven Press, 163-169, 1983.

30. Kung PC, Berger CL, Estabrook A and Edelson RL. Monoclonal antibodies for clinical investigation of human T lymphocytes. Int J Dermatol 22: 67, 1983.

31. Berger CL and Edelson RL. Peripheral blood of patients with cutaneous T-cell lymphoma: studies using monoclonal antibodies. J Cutan Pathol 10: 467-478, 1983.

32. Patterson JAK and Edelson RL. Cutaneous T cell lymphoma. In: Your Patient and Cancer, pp. 91-98.

33. Patterson JAK and Edelson RL. Interaction of T lymphocytes with the epidermis: immunopathological studies. J Cut Path 10: 540-549, 1983.

34. Edelson RL. Pathogenesis of T cell lymphoma of skin. J Amer Acad Derm 9 (6): 957-960, 1983.

35. Bisaccia E and Edelson RL. Cutaneous T cell lymphoma. In Dermatologic Allergy and Immunology. C.V. Mosby, 1984.

36. Edelson RL. Extracorporeal Photopheresis. Photodermatology (Editorial) Vol. 1 (5): 209-210, 1984.

37. Shapiro PE and Edelson RL. Effects of retinoids on the immune system. In Retinoids: New Trends in Research and Therapy. Retinoid Symposium, Geneva. J.H. Saurat (ed), Karger, pp. 225-235, 1985.

38. Toback AC and Edelson RL. Pathogenesis of cutaneous T cell lymphoma. In: Dermatologic Clinics Vol. 3 pp. 605-614, October, 1985.

39. Santella RM, Gasparro FP and Edelson RL. Quantification of methoxsalen-DNA adducts with specific antibodies. In: Carcinogenicity of Alkylating Cytostatic Drugs. Schmahl, D. and Kaldor, J.M. (eds.) Lyon IARC 78: 127-139, 1986.

40. Knobler RM and Edelson RL. Cutaneous T Cell Lymphoma. Medical Clinics of North America 70: No. 1, 109-138, 1986.

41. Knobler RM and Edelson RL. Lymphoma Cutis: T-Cell Type. In Lymphoproliferative Disorders of the Skin, editors George F. Murphy and Martin C. Mihm, Jr. Chapter 7 pp. 176-204, 1986.

42. Edelson RL. Cutaneous T cell lymphoma. (1987 Dohi Memorial Lecture) The Jrnl of Dermatology 14: 397-410, 1987.

43. Patterson JAK and Edelson RL. Cutaneous T cell lymphoma and other leukemic and lymphomatous infiltrates of the skin. In: Dermatology in General Medicine. 3rd Ed. Fitzpatrick TP, Eisen AZ, Wolff K, Freedberg IM and Austen KF. McGraw Hill 1086-1118, 1987.

44. Edelson RL. Photopheresis therapy of cutaneous T cell lymphoma. Japanese Jrnl of Dermatology 97: No. 12, 1361-1390, 1987.

45. Kupper TS and Edelson RL. The role of cytokines in the pathophysiology of T cell mediated skin disease. J Dermatology 14: 517-523, 1987.

46. Patterson JAK and Edelson RL. Skin diseases caused by specific cell types. In Immunological Diseases, 4th Ed. Max Samter (ed), Little Brown & Co. 1988.

47. Teltscher J, Shrishailam Y, Estabrook A, Berger C, Edelson R and Bayley H. Phototoxic Liposomes for Selective Destruction of T Lymphocytes: Experiments under Physiological Conditions. In: Liposomes as Drug Carriers: Trends and Progress. G. Gregoriadis ed. Wiley and Sons Ltd. 783-792, 1988.

48. Heald PW and Edelson RL. Photopheresis for T cell mediated diseases. Adv Derm 3: 25-40, 1988.

49. Knobler RM, Honigsmann H and Edelson RL. Psoralen phototherapies in psoralen - DNA photobiology. CRC Press 1988.

50. Heald PW, Edelson RL. Photopheresis for cutaneous T-cell lymphoma. Keio Med Journal, 37: 155, 1988.

51. Heald PW, Edelson RL: Cutaneous T Cell Lymphoma. In Decision Making in Oncology, Schein P (ed). 1989.

52. Edelson RL. Update on Photopheresis. Dermatology Foundation Progress in Dermatology Vol. 23, No. 1, March 1989.

53. Heald PW, Edelson RL: Photopheresis. In Photochemotherapy. Abel L (ed). 1989.

54. Heald PW, Edelson RL: Cutaneous T Cell Lymphoma. In Dermatology. Moschella S, Hurley H (eds). 1989.

55. Heald PW, Perez MI, McKiernan G, Christensen I, Edelson RL. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma. Apheresis, 1:443-447, 1990.

56. Edelson RL. Treatment of Cutaneous T Cell Lymphoma. Curr Probl Derm, Karger S., Pub. Basel, Switzerland. Vol. 19,: pp 226-237, 1990.

57. Gasparro F, Bevilacqua P, Goldminz D, Edelson R. Repair of 8-MOP Photoadducts in Human Lymphocytes. DNA Damage and Repair in Human Tissues. Plenum Press 137-148, 1990.

58. Heald PW and Edelson RL. Pathophysiology of Cutaneous T Cell Lymphomas. In Pathophysiology of Cutaneous Diseases. Soter N, Baden H (eds). 1990.

59. Heald PW, Edelson RL. Cutaneous T Cell Lymphoma. In Hematology: Basic principles and practice. Benz EJ, Cohen HF, Furie B, Hoffman R, Shattil S (eds). Churchill Livingstone Press, New York, NY. Chapter 78, pp. 1008-1020, 1991.

60. Heald PW, Edelson RL. Tumors of the lymphoreticular system. In Clinical Dermatology. Demis J (ed). 1991.

61. Heald PW, Edelson RL. Photopheresis. In Photochemotherapy. Abel L (ed). 1991.

62. Heald PW, Edelson RL: Photopheresis: Past, present and future. In: Recent Advances in Dermatology. Churchill Livingstone, Robert Champion and Richard Pye, Editors. 9: Ch 4: 49-62, 1991.

63. Heald PW, Perez M, Edelson R: Photopheresis of cutaneous T-cell lymphoma: Response rates and mechanism of action. Lymphomas of the Skin. Yamada M, Nakajima H (eds) 1991.

64. Edelson R, Heald P, Perez M, Rook A. Photopheresis Update. Dermatology Foundation Progress in Dermatology, Vol. 25 1991.

65. Heald PW, Edelson RL. Cutaneous T Cell Lymphoma. In Hematology, 2E: Basic principles and practice. Churchill Livingstone Press, New York, NY. Chapter 85, In Press, 1994.

66. Edelson R. Cutaneous T cell lymphoma: a malignancy of a distinct subset of "cutaneous T cells". Cutaneous Lymphoma - 1993, edited by Mizuho Yamada, Honorary Editor and Masahiro Takigawa, Editor. Mokko Press, Hammamatsu, Japan, 1994.

67. Edelson, R, Heald P, Perez M, Berger C. Extracorporeal Photochemotherapy. Biologic Therapy Updates. 1995.

1. Gasparro FP and Edelson RL. Extracorporeal Photochemotherapy. Photoimmunology. Jean Krutmann and Craig A. Elmets, Eds. 17:231-245, 1995.

69. Heald, PW, Shapiro PE, Madison JF, Leboit PE, Edelson R. Cutaneous T-Cell Lymphoma: Relevant Scientific Summary of Neoplastic T-Cells: Classic Disease Description and Pathology. Cutaneous Medicine and Surgery, Kenneth Arndt, Philip LeBoit, June Robinson, and Bruce U. Wintroub, Eds. 158:1639-1659, 1995.

70. Lim H, Edelson RL. Photopheresis for the Treatment of Cutaneous T-cell Lymphoma. Monograph. Hematol Oncol Clin North Am, Howard K. Koh, Francine M. Foss, Guest Editors. Vol. 9(5) 1117-26, 1995.

71. Edelson RL. Extracorporeal Photochemotherapy: Cellular Therapy for Cutaneous T-Cell Lymphoma, Selected Autoimmune Disorders, and Organ Transplant Rejection. Therapeutic Immunology edited by Drs. Austen, Burakoff, Rosen and Strom. Chapter 50:615-627, 1996.

72. Wilson LD, Kacinski BM, Edelson RL, Heald PW. Cutaneous T-Cell Lymphomas Cancer: Principles & Practice of Oncology edited by Vincent T. DeVita, Jr., MD, Samuel Hellman, MD, Steven A. Rosenberg, MD, PhD. Chapter 44(4):2220-2232, 1997.

1. Bolognia JL, Edelson RL. Spread of antibiotic-resistant bacteria from acne patients to personal contacts - a problem beyond the skin? The Lancet editorial, David Frankel Editor. 350:972-973, 1997.

74. Edelson R.L. Cutaneous Allergy. N Engl J Med. 337:504, 1997.

75. Edelson RL and Berger C. Extracorporeal photochemotherapy. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers Limited, London, England, pp. 396-408, 1999.

1. Heald PW and Edelson RL. Cutaneous T Cell Lymphoma. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 138-145, 1999.
2. Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the immunobiology and immunotherapy of cutaneous T cell lymphoma. In Advances in Dermatology, Volume 20, Chapter 8, pp. 217-235, 2005.
3. Berger CL, Shofner J, Vasquez JG, Mariwalla K and Edelson RL. Cancer Immunotherapy. Cancer Therapy Vol. 3, pp 1-17, 2005
4. Berger CL, Shofner J, Vasquez JG, Mariwalla K, Edelson RL. Cancer Immunotherapy. Cancer Therapy 4:81-98, 2006.
5. Berger CL, Edelson R. Dendritic cell immunotherapy in malignancies. Drugs of the Future 2007, 32: 1-9.
6. Shofner JD, Vasquez JG, Berger CL, Edelson RL. Improved generation of anti-tumor immunity by antigen dose limitation. J Immune Based Ther Vaccines 5:2:1476-8518, 2007.
7. Berger CL, Heald P, Edelson R: Cutaneous T cell lymphoma: advances in immunology translate into clinical practice. Chapter, Immunobiology of the skin. Sem Saeland Ed. (in press) 2008
8. Berger CL, Heald P, Girardi M, Edelson RL: Cutaneous T cell lymphoma: Translating immunobiology into therapeutic opportunities. Gital Dermatol Venereol 2008: 143-43-54.
9. Berger CL, Edelson R. Cancer immunotherapy: from promise to practice. Drugs of the Future 2008, 33(5):
10. Mutyambizi K, Berger CL, Edelson RL. The balance between immunity and tolerance; The role of Langerhans cells. Cellular and Molecular Life Sciences, 2008.
11. Foss F, Edelson R, Wilson L. Cutaneous Lymphomas, CANCER: Principles & Practices of Oncology, 9th Edition, edited by Vincent T. DeVita, Jr., MD, Theodore S. Lawrence, MD, PhD, Steven A. Rosenberg, MD, PhD.
12. Edelson RL. [Partnering with skin to outsmart cancer: following leads provided by tumor- specific T cells.](https://www.ncbi.nlm.nih.gov/pubmed/27178683) Semin Oncol. 43:328-30, 2016.
13. Edelson, R, Wu Y, Schneiderman J. American council on ECP (ACE): Why now ?J Clin Aphere. 33: 464-468, 2018.
14. Hanlon D., Sobolev O., Ventura A., Vassall A., Kibbi N., Han P., Yurter A., Robinson A., Filler R., Tatsuno K. and Edelson RL. Rapid Production of Physiologic Dendritic Cells (phDC) for Immunotherapy. “Dendritic Cell Reprogramming”, 2019 *In press*, Springer Methods in Molecular Biology, 2020.
15. Han, P., Hanlon, D., Sobolev, O., Chaudhury R and Edelson, R. Ex vivo DC generation – A critical comparison of current approaches. 2019 *In press,* International Review of Cell and Molecular Biology (IRCMB) 2020.

Books

Milstone L and Edelson R. Endocrine metabolic and immunologic functions of keratinocytes. Annals NY Acad Science, Volume 548, 1988.

Edelson R. *Antigen and Clone-Specific Immunoregulation*. Editor, Annals NY Acad Science, Volume 636, 1991.

A.C. Chu and R.L. Edelson. Malignant Tumors of the Skin. Editors. Edward Arnold Publishers Limited, London, England, 1999.

Edelson Richard L. and DeVita, Jr., Vincent T. *Cutaneous T Cell Lymphoma.* Editor, Annals NY Acad Science, Volume 941, 2001.

Edelson, Richard L. Editor, *Transfusion and Apheresis Science.* Vol. 26 Issue 3, June 2002.

Berger, C.L., Heald, P., Edelson, R., Cutaneous T cell lymphoma: Advances in immunology translate into clinical practice. Recent Advances in Skin Immunology, 2008: 263-282.

Patents

1. 4,321,919, Mar. 30, 1982, Method and system for externally treating human blood, Edelson, Richard L. (Columbia University)

2. 4,398,906, Aug. 16, 1983, Method for externally treating the blood, Edelson, Richard L. (Columbia University)

3. 4,428,744, Jan. 31, 1984, Method and system for externally treating the blood, Edelson, Richard L. (Columbia University)

4. 4,464,166, Aug. 7, 1984, Method for externally treating the blood, Edelson, Richard L. (Columbia University)

5. 4,612,007, Sep. 16, 1986, Method and system for externally treating the blood, Edelson, Richard L. (Yale University)

6. 4,613,322, Sep. 23, 1986, Method and system for externally treating the blood, Edelson, Richard L. (Yale University)

7. 4,684,521, Aug. 4, 1987, Method and system for externally treating the blood, Edelson. (Yale University)

8. 4,683,889, Aug. 4, 1987, Method and system for externally treating the blood, Edelson, Richard. (Yale University)

9. 4,838,852, Jun. 13, 1989, Active specific immune suppression, Edelson, Richard L., Westport, Connecticut Tripodi, Daniel J., Lebanon. (Yale University)

10. 4,868,311, Sep. 19, 1989, Biotinylated psoralens, Saffran, Wilma A., Forest Hills, New York Edelson, Richard L., Gasparro, Francis P., Welsh, John T., Cantor, Charles R. (Columbia University)

11. 5,147,289, Sep. 15, 1992, Non-specific immune system enhancement, Edelson, Richard L. (Yale University)

12. 5,114,721, May 19, 1992, Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases, Cohen, Irun R. (Yale University and Weizmann Institute)

13. 5,256,648, Oct. 26, 1993, Selective inhibition of gene expression by photoactivatable oligonucleotides, Gasparro, Francis P, Edelson, Richard L. (Yale University)

14. 5,383,847, Jan. 24, 1995, Non-specific immune system enhancement, Edelson, Richard L. (Yale University)

15. 5,462,733, Oct. 31, 1995, Immune system modulation using psoralens activated with visible light, Edelson, Richard L. (Yale University)

16. 5,651,993, Jul. 29, 1997, Specific immune system modulation, Edelson, Richard L. (Yale University)

17. 5,820,872, Oct.13, 1998, Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor, Edelson, Richard L. (Yale University)

18. 20010053355, December 20, 2001, Methods for inducing the differentiation of monocytes into functional dendritic cells, Edelson, Richard Leslie. (Yale University)

19. 6,355,238, March 12, 2002, Specific immune system modulation, Edelson, Richard L., Westport, Connecticut, Gasparro, Francis P., Hamden, Connecticut, Tigelaar, Robert E. (Yale University)

20. 20020004044, January 10, 2002, Methods for inducing the differentiation of monocytes into functional dendritic cells, Edelson, Richard Leslie. (Yale University)

#### 22. 20050158856, July 1, 2004, [Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials](http://patents.justia.com/patent/20050158856), Richard Edelson, Carole Berger, Douglas Hanlon, Hong Shen. (Yale University)

23. 20050084966, April 21, 2005, [Methods for inducing the differentiation of blood monocytes into functional dendritic cells](http://patents.justia.com/patent/20050084966), Richard Edelson, Carole Berger. (Yale University)

21. 20070281354, May 16, 2007, [Methods for inducing the differentiation of blood monocytes into functional dendritic cells](http://patents.justia.com/patent/20070281354), Richard Edelson, Carole Berger. (Yale University)